Literature DB >> 25460020

Rodent models of treatment-resistant depression.

Barbara J Caldarone1, Venetia Zachariou2, Sarah L King3.   

Abstract

Major depression is a prevalent and debilitating disorder and a substantial proportion of patients fail to reach remission following standard antidepressant pharmacological treatment. Limited efficacy with currently available antidepressant drugs highlights the need to develop more effective medications for treatment- resistant patients and emphasizes the importance of developing better preclinical models that focus on treatment- resistant populations. This review discusses methods to adapt and refine rodent behavioral models that are predictive of antidepressant efficacy to identify populations that show reduced responsiveness or are resistant to traditional antidepressants. Methods include separating antidepressant responders from non-responders, administering treatments that render animals resistant to traditional pharmacological treatments, and identifying genetic models that show antidepressant resistance. This review also examines pharmacological and non-pharmacological treatments regimes that have been effective in refractory patients and how some of these approaches have been used to validate animal models of treatment-resistant depression. The goals in developing rodent models of treatment-resistant depression are to understand the neurobiological mechanisms involved in antidepressant resistance and to develop valid models to test novel therapies that would be effective in patients that do not respond to traditional monoaminergic antidepressants.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Animal model; Antidepressant; Behavior; Genetic; Pharmacology; Treatment resistant depression

Mesh:

Year:  2014        PMID: 25460020      PMCID: PMC4423538          DOI: 10.1016/j.ejphar.2014.10.063

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  203 in total

Review 1.  A neurotrophic model for stress-related mood disorders.

Authors:  Ronald S Duman; Lisa M Monteggia
Journal:  Biol Psychiatry       Date:  2006-04-21       Impact factor: 13.382

2.  Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.

Authors:  Madhukar H Trivedi; A John Rush; Stephen R Wisniewski; Andrew A Nierenberg; Diane Warden; Louise Ritz; Grayson Norquist; Robert H Howland; Barry Lebowitz; Patrick J McGrath; Kathy Shores-Wilson; Melanie M Biggs; G K Balasubramani; Maurizio Fava
Journal:  Am J Psychiatry       Date:  2006-01       Impact factor: 18.112

Review 3.  Recent advances in animal models of chronic antidepressant effects: the novelty-induced hypophagia test.

Authors:  Stephanie C Dulawa; Rene Hen
Journal:  Neurosci Biobehav Rev       Date:  2005       Impact factor: 8.989

4.  Use of latency to immobility improves detection of antidepressant-like activity in the behavioral despair test in the mouse.

Authors:  Vincent Castagné; Roger D Porsolt; Paul Moser
Journal:  Eur J Pharmacol       Date:  2009-06-21       Impact factor: 4.432

5.  Quantitative trait loci mapping and gene network analysis implicate protocadherin-15 as a determinant of brain serotonin transporter expression.

Authors:  R Ye; A M D Carneiro; Q Han; D Airey; E Sanders-Bush; B Zhang; L Lu; R Williams; R D Blakely
Journal:  Genes Brain Behav       Date:  2014-02-06       Impact factor: 3.449

Review 6.  A review of the clinical, economic, and societal burden of treatment-resistant depression: 1996-2013.

Authors:  David A Mrazek; John C Hornberger; C Anthony Altar; Irina Degtiar
Journal:  Psychiatr Serv       Date:  2014-08-01       Impact factor: 3.084

7.  Repeated electroconvulsive stimuli have long-lasting effects on hippocampal BDNF and decrease immobility time in the rat forced swim test.

Authors:  Bingjin Li; Katsuya Suemaru; Ranji Cui; Hiroaki Araki
Journal:  Life Sci       Date:  2007-01-27       Impact factor: 5.037

8.  Intra- and interstrain differences in models of "behavioral despair".

Authors:  F Bai; X Li; M Clay; T Lindstrom; P Skolnick
Journal:  Pharmacol Biochem Behav       Date:  2001 Oct-Nov       Impact factor: 3.533

9.  A randomized, double-blind, placebo-controlled trial of pramipexole augmentation in treatment-resistant major depressive disorder.

Authors:  Cristina Cusin; Nadia Iovieno; Dan V Iosifescu; Andrew A Nierenberg; Maurizio Fava; A John Rush; Roy H Perlis
Journal:  J Clin Psychiatry       Date:  2013-07       Impact factor: 4.384

10.  NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses.

Authors:  Anita E Autry; Megumi Adachi; Elena Nosyreva; Elisa S Na; Maarten F Los; Peng-fei Cheng; Ege T Kavalali; Lisa M Monteggia
Journal:  Nature       Date:  2011-06-15       Impact factor: 49.962

View more
  12 in total

Review 1.  Strategies for Treatment-Resistant Depression: Lessons Learned from Animal Models.

Authors:  Gislaine Zilli Réus; Airam Barbosa de Moura; Laura Araújo Borba; Helena Mendes Abelaira; João Quevedo
Journal:  Mol Neuropsychiatry       Date:  2019-05-21

2.  Long-lasting reflexive and nonreflexive pain responses in two mouse models of fibromyalgia-like condition.

Authors:  Beltrán Álvarez-Pérez; Meritxell Deulofeu; Judit Homs; Manuel Merlos; José Miguel Vela; Enrique Verdú; Pere Boadas-Vaello
Journal:  Sci Rep       Date:  2022-06-12       Impact factor: 4.996

3.  When Enough Is Enough: Decision Criteria for Moving a Known Drug into Clinical Testing for a New Indication in the Absence of Preclinical Efficacy Data.

Authors:  Jill M Pulley; Rebecca N Jerome; Nicole M Zaleski; Jana K Shirey-Rice; Andrea J Pruijssers; Robert R Lavieri; Somsundaram N Chettiar; Helen M Naylor; David M Aronoff; David A Edwards; Colleen M Niswender; Laura L Dugan; Leslie J Crofford; Gordon R Bernard; Kenneth J Holroyd
Journal:  Assay Drug Dev Technol       Date:  2017-12-01       Impact factor: 1.738

Review 4.  Role of Ketamine in the Treatment of Psychiatric Disorders.

Authors:  Sahar Derakhshanian; Maxine Zhou; Alexander Rath; Rachel Barlow; Sarah Bertrand; Caroline DeGraw; Christopher Lee; Jamal Hasoon; Alan D Kaye
Journal:  Health Psychol Res       Date:  2021-06-22

Review 5.  Novel drug developmental strategies for treatment-resistant depression.

Authors:  Éva Borbély; Mária Simon; Eberhard Fuchs; Ove Wiborg; Boldizsár Czéh; Zsuzsanna Helyes
Journal:  Br J Pharmacol       Date:  2022-01-26       Impact factor: 9.473

6.  Bio-behavioural changes in treatment-resistant socially isolated FSL rats show variable or improved response to combined fluoxetine-olanzapine versus olanzapine treatment.

Authors:  K Mncube; B H Harvey
Journal:  IBRO Neurosci Rep       Date:  2022-09-05

Review 7.  Dendritic Spines in Depression: What We Learned from Animal Models.

Authors:  Hui Qiao; Ming-Xing Li; Chang Xu; Hui-Bin Chen; Shu-Cheng An; Xin-Ming Ma
Journal:  Neural Plast       Date:  2016-01-10       Impact factor: 3.599

8.  Dysfunction of Serotonergic and Dopaminergic Neuronal Systems in the Antidepressant-Resistant Impairment of Social Behaviors Induced by Social Defeat Stress Exposure as Juveniles.

Authors:  Sho Hasegawa; Yuriko Miyake; Akira Yoshimi; Akihiro Mouri; Hirotake Hida; Kiyofumi Yamada; Norio Ozaki; Toshitaka Nabeshima; Yukihiro Noda
Journal:  Int J Neuropsychopharmacol       Date:  2018-09-01       Impact factor: 5.176

Review 9.  Animal models of major depression: drawbacks and challenges.

Authors:  Barbara Planchez; Alexandre Surget; Catherine Belzung
Journal:  J Neural Transm (Vienna)       Date:  2019-10-04       Impact factor: 3.575

10.  Ketamine and its metabolite, (2R,6R)-HNK, restore hippocampal LTP and long-term spatial memory in the Wistar-Kyoto rat model of depression.

Authors:  Lily R Aleksandrova; Yu Tian Wang; Anthony G Phillips
Journal:  Mol Brain       Date:  2020-06-16       Impact factor: 4.041

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.